0 19 Platelet-activating platelet-activating JJ 20 26 factor factor NN 27 37 stimulates stimulate VBZ 38 51 transcription transcription NN 52 54 of of IN 55 58 the the DT 59 74 heparin-binding heparin-binding JJ 75 84 epidermal epidermal JJ 85 91 growth growth NN 92 103 factor-like factor-like JJ 104 110 growth growth NN 111 117 factor factor NN 118 120 in in IN 121 130 monocytes monocyte NNS 130 131 . . . 132 143 Correlation correlation NN 144 148 with with IN 149 151 an an DT 152 161 increased increase VBN 162 167 kappa kappa NN 168 169 B B NNP 170 177 binding binding NN 178 186 activity activity NN 186 187 . . . 189 194 Human human JJ 195 205 peripheral peripheral JJ 206 211 blood blood NN 212 221 monocytes monocyte NNS 222 231 responded respond VBD 232 234 to to TO 235 246 stimulation stimulation NN 247 249 of of IN 250 269 platelet-activating platelet-activating JJ 270 276 factor factor NN 277 278 ( ( ( 278 281 PAF PAF NNP 281 282 ) ) ) 283 287 with with IN 288 301 up-regulation up-regulation NN 302 304 of of IN 305 308 the the DT 309 319 transcript transcript NN 320 323 for for IN 324 339 heparin-binding heparin-binding JJ 340 349 epidermal epidermal JJ 350 356 growth growth NN 357 368 factor-like factor-like JJ 369 375 growth growth NN 376 382 factor factor NN 383 384 ( ( ( 384 390 HB-EGF HB-EGF NNP 390 391 ) ) ) 391 392 , , , 393 394 a a DT 395 401 potent potent JJ 402 409 mitogen mitogen NN 410 413 for for IN 414 422 vascular vascular JJ 423 429 smooth smooth JJ 430 436 muscle muscle NN 437 442 cells cell NNS 442 443 . . . 444 448 This this DT 449 457 function function NN 458 460 of of IN 461 464 PAF PAF NNP 465 468 was be VBD 469 477 observed observe VBN 478 480 at at IN 481 490 nanomolar nanomolar JJ 491 505 concentrations concentration NNS 506 508 of of IN 509 512 the the DT 513 519 ligand ligand NN 519 520 , , , 521 529 starting start VBG 530 532 at at IN 533 535 30 30 CD 536 539 min min NN 540 545 after after IN 546 557 stimulation stimulation NN 557 558 . . . 559 562 The the DT 563 574 PAF-induced paf-induced JJ 575 588 up-regulation up-regulation NN 589 591 of of IN 592 598 HB-EGF HB-EGF NNP 599 603 mRNA mRNA NNP 604 607 was be VBD 608 619 accompanied accompany VBN 620 622 by by IN 623 625 an an DT 626 634 increase increase NN 635 637 in in IN 638 643 kappa kappa NN 644 645 B B NNP 646 653 binding binding NN 654 662 activity activity NN 662 663 . . . 664 669 These these DT 670 679 functions function NNS 680 682 of of IN 683 686 PAF PAF NNP 687 695 appeared appear VBD 696 698 to to TO 699 701 be be VB 702 710 mediated mediate VBN 711 718 through through IN 719 722 the the DT 723 727 cell cell NN 728 735 surface surface NN 736 739 PAF PAF NNP 740 749 receptors receptor NNS 749 750 , , , 751 753 as as IN 754 757 two two CD 758 761 PAF PAF NNP 762 770 receptor receptor NN 771 782 antagonists antagonist NNS 782 783 , , , 784 787 WEB WEB NNP 788 792 2086 2086 CD 793 796 and and CC 797 806 L-659,989 L-659,989 NNP 806 807 , , , 808 815 blocked block VBD 816 820 both both CC 821 824 the the DT 825 838 up-regulation up-regulation NN 839 841 of of IN 842 848 HB-EGF HB-EGF NNP 849 853 mRNA mRNA NNP 854 857 and and CC 858 863 kappa kappa NNP 864 865 B B NNP 866 873 binding binding NN 874 882 activity activity NN 883 890 induced induce VBN 891 893 by by IN 894 897 PAF PAF NNP 897 898 . . . 899 902 The the DT 903 914 antagonists antagonist NNS 914 915 , , , 916 923 however however RB 923 924 , , , 925 928 had have VBD 929 931 no no DT 932 938 effect effect NN 939 941 on on IN 942 949 phorbol phorbol NN 950 963 ester-induced ester-induced JJ 964 977 up-regulation up-regulation NN 978 980 of of IN 981 987 HB-EGF HB-EGF NNP 988 992 mRNA mRNA NNP 993 996 and and CC 997 1002 kappa kappa NNP 1003 1004 B B NNP 1005 1012 binding binding NN 1013 1021 activity activity NN 1021 1022 . . . 1023 1035 Pretreatment Pretreatment NNP 1036 1038 of of IN 1039 1048 monocytes monocyte NNS 1049 1053 with with IN 1054 1063 pertussis pertussis NN 1064 1069 toxin toxin NN 1070 1079 inhibited inhibit VBD 1080 1085 these these DT 1086 1095 functions function NNS 1096 1098 of of IN 1099 1102 PAF PAF NNP 1102 1103 , , , 1104 1111 whereas whereas IN 1112 1119 cholera cholera NN 1120 1125 toxin toxin NN 1126 1129 had have VBD 1130 1132 no no DT 1133 1143 inhibitory inhibitory JJ 1144 1150 effect effect NN 1150 1151 . . . 1152 1163 Pyrrolidine Pyrrolidine NNP 1164 1179 dithiocarbamate dithiocarbamate NN 1179 1180 , , , 1181 1183 an an DT 1184 1193 inhibitor inhibitor NN 1194 1197 for for IN 1198 1206 NF-kappa NF-kappa NNP 1207 1208 B B NNP 1209 1219 activation activation NN 1219 1220 , , , 1221 1229 markedly markedly RB 1230 1237 reduced reduce VBD 1238 1252 PAF-stimulated paf-stimulated JJ 1253 1258 kappa kappa NN 1259 1260 B B NNP 1261 1268 binding binding NN 1269 1277 activity activity NN 1278 1280 as as RB 1281 1285 well well RB 1286 1288 as as IN 1289 1302 up-regulation up-regulation NN 1303 1305 of of IN 1306 1312 HB-EGF HB-EGF NNP 1313 1317 mRNA mRNA NNP 1317 1318 . . . 1319 1324 These these DT 1325 1332 results result NNS 1333 1340 suggest suggest VBP 1341 1342 a a DT 1343 1352 potential potential JJ 1353 1357 role role NN 1358 1360 of of IN 1361 1364 PAF PAF NNP 1365 1367 in in IN 1368 1374 HB-EGF HB-EGF NNP 1375 1385 expression expression NN 1386 1389 and and CC 1390 1397 provide provide VBP 1398 1406 evidence evidence NN 1407 1411 that that IN 1412 1416 this this DT 1417 1428 stimulation stimulation NN 1429 1432 may may MD 1433 1438 occur occur VB 1439 1446 through through IN 1447 1456 increased increase VBN 1457 1462 kappa kappa NN 1463 1464 B B NNP 1465 1472 binding binding NN 1473 1481 activity activity NN 1481 1482 . . .